Public Health Supply Chains and Drug Pricing: The Government Pharmaceutical Organization (GPO) and Compulsory Licensing
Introduction
When designing a national universal health coverage scheme, the primary fiscal threat is rarely the cost of basic consultations—it is the open-ended expenditure driven by patented pharmaceuticals and high-technology consumables. In low- and middle-income nations, access to lifesaving therapeutic agents is frequently curtailed by intellectual property regimes that insulate monopolistic drug pricing from market competition.
Thailand’s response to this vulnerability represents one of the most assertive, legally sophisticated public health procurement strategies in the developing world.
Through the operational arm of the Government Pharmaceutical Organization (GPO) and the targeted enforcement of Government Use Licenses (Compulsory Licensing) under international trade law, the Royal Thai Government insulated its Universal Coverage Scheme (UCS) against price shocks. Examining Thailand’s pharmaceutical governance requires analyzing the statutory mandate of the GPO, the institutional mechanics of the National Drug System, the watershed 2006–2008 compulsory licensing campaign, and the evolving economic diplomacy governing biopharmaceutical manufacturing and trade agreements.
Institutional Pillars of the Thai Drug System
Thailand’s pharmaceutical access strategy functions through three synchronized public bodies that link legal manufacturing, therapeutic evaluation, and consolidated monopsonistic purchasing:
+-----------------------------------------------------------------------------------+
| THAILAND'S PHARMACEUTICAL GOVERNANCE TRIAD |
+-----------------------------------------------------------------------------------+
| 1. National Drug System Development Committee (NDSDC) |
| • Formulates the National Drug Policy |
| • Curates the National List of Essential Medicines (NLEM) |
+-----------------------------------------------------------------------------------+
▼
| 2. Government Pharmaceutical Organization (GPO) |
| • State-owned drug developer, industrial manufacturer, and primary importer |
| • Supplies public sector hospitals via preferential statutory procurement |
+-----------------------------------------------------------------------------------+
▼
| 3. National Health Security Office (NHSO) & Central Purchasing |
| • Leverages consolidated national patient volume to negotiate single prices |
| • Orchestrates bulk distribution pipelines directly to regional hospitals |
+-----------------------------------------------------------------------------------+
1. The Government Pharmaceutical Organization (GPO / องค์การเภสัชกรรม)
Established under the Government Pharmaceutical Organization Act B.E. 2509 (1966), the GPO operates as an autonomous state enterprise under the administrative oversight of the Ministry of Public Health. Its statutory purpose is to formulate, manufacture, reserve, and distribute quality pharmaceutical products at prices affordable to the public sector.
Operating extensive manufacturing sites across Bangkok and Pathum Thani, the GPO produces high volumes of generic small-molecule therapeutics—such as anti-hypertensives, oral hypoglycemics, broad-spectrum antibiotics, and central nervous system agents.
Under national public procurement regulations, state hospitals are legally required to purchase designated essential generic lines directly from the GPO, provided the organization’s prices remain equal to or lower than competing market options. This arrangement provides the GPO with guaranteed baseline demand while insulating public hospitals from private commercial drug-broker markups.
2. The National List of Essential Medicines (NLEM / บัญชียาหลักแห่งชาติ)
Curated by subcommittees under the National Drug System Development Committee (NDSDC), the NLEM is the core formulary for the entire Thai health architecture. A drug’s inclusion on the NLEM dictates whether it is covered under the Universal Coverage Scheme, the Social Security Scheme, and the Civil Servant Medical Benefit Scheme.
Crucially, the selection process uses health technology assessment (HTA) principles coordinated by the Health Intervention and Technology Assessment Program (HITAP). Rather than relying solely on clinical efficacy, additions to the NLEM undergo comparative cost-effectiveness analyses, budget impact assessments, and domestic societal valuations before reimbursement approval.
3. Centralized Monopsonistic Bargaining
For specialized, high-cost therapies included on the NLEM—such as biologic cancer treatments, hepatitis C direct-acting antivirals, and renal immunosuppressants—the NHSO bypasses fragmented, hospital-by-hospital procurement. Acting as a monopsonist purchaser, the NHSO pools the therapeutic demand of over 47 million UCS beneficiaries, negotiating directly with multinational pharmaceutical patent holders. If negotiations fail to lower prices within cost-effective thresholds, the statutory system deploys sovereign trade mechanisms to ensure public access.
The 2006–2008 Watershed: Compulsory Licensing in Action
The defining conflict in Thailand’s health supply history occurred between November 2006 and February 2008, when the Ministry of Public Health and the NHSO issued Government Use Licenses (Compulsory Licenses – CLs) on seven critical, patented life-saving medications.
+-----------------------------------------------------------------------------------+
| THE SEVEN DRUGS SUBJECTED TO THAI COMPULSORY LICENSES |
+-------------------+-----------------------------+---------------------------------+
| Therapeutic Class | Generic Chemical Name | Proprietary Brand Reference |
+-------------------+-----------------------------+---------------------------------+
| Antiretroviral | Efavirenz (EFV) | Sustiva (Bristol-Myers Squibb) |
| (HIV/AIDS) | Lopinavir / Ritonavir (LPV/r)| Kaletra (Abbott Laboratories) |
+-------------------+-----------------------------+---------------------------------+
| Cardiovascular | Clopidogrel | Plavix (Sanofi-Aventis) |
+-------------------+-----------------------------+---------------------------------+
| Oncology | Letrozole | Femara (Novartis) |
| | Docetaxel | Taxotere (Sanofi-Aventis) |
| | Erlotinib | Tarceva (Roche) |
| | Imatinib | Gleevec (Novartis) |
+-------------------+-----------------------------+---------------------------------+
Legal Basis: The TRIPS Agreement and Doha Declaration
Under Section 51 of the Thai Patent Act B.E. 2522 (as amended in 1999) and Article 31 of the World Trade Organization’s (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), sovereign governments possess the legal authority to authorize the use of a patented invention without the consent of the patent holder for public, non-commercial purposes.
This right was affirmed by the Doha Declaration on the TRIPS Agreement and Public Health (2001), which established that patent rights should not prevent member states from taking measures to protect public health and promote access to medicines for all.
Thailand did not revoke the patents; rather, the government invoked public, non-commercial use licenses, offering the patent holders a statutory royalty rate (typically 0.5% to 1.5% of net sales). This authorization allowed:
-
The domestic industrial synthesis of bioequivalent generic versions by the GPO.
-
The emergency importation of lower-cost WHO-prequalified generic equivalents from Indian manufacturers while GPO local capacity was ramped up.
Clinical and Fiscal Impact
The economic and health ramifications were immediate and transformative:
-
Antiretroviral Scalability: Prior to the CL on Efavirenz, the proprietary drug cost approximately 2,200 Baht per patient per month, limiting access across the public HIV program. Generic imports and subsequent GPO formulations reduced this figure to roughly 650 Baht per month. This cost reduction enabled the MOPH to scale up universal antiretroviral therapy (ART) nationwide, cutting AIDS-related mortality and secondary opportunistic infections across the country.
-
Cardiac Care: The cost of Clopidogrel—essential for preventing secondary thrombosis following acute myocardial infarction and coronary stenting—dropped by over 90%, transforming an unaffordable tertiary medicine into a widely accessible secondary prevention standard in district hospitals.
-
Oncology Savings: Compulsory licensing for advanced oncology therapies significantly reduced treatment-course costs, preventing catastrophic household expenditures for low-income patients. In the case of Imatinib (Gleevec), the state’s actions prompted the manufacturer to establish a direct-access donation program for UCS patients who met specific poverty criteria.
Geopolitical Retaliation and Economic Diplomacy
Thailand’s deployment of compulsory licensing triggered swift pushback from multinational pharmaceutical firms and international trade bodies:
Trade Repercussions and the Special 301 Report
In April 2007, the Office of the United States Trade Representative (USTR) elevated Thailand from its “Watch List” to the “Priority Watch List” under Section 301 of the Trade Act of 1974. The USTR cited concerns regarding intellectual property enforcement and transparency in the issuance of compulsory licenses.
Concurrently, several multinational pharmaceutical corporations protested the measures:
-
Abbott Laboratories withdrew all pending new drug applications from the Thai Food and Drug Administration (FDA), including a novel, heat-stable formulation of lopinavir/ritonavir that did not require refrigeration—a critical feature for tropical, rural healthcare settings.
+-----------------------------------------------------------------------------------+
| THE COMPULSORY LICENSING PARADOX |
+-----------------------------------------------------------------------------------+
| PUBLIC HEALTH BENEFIT: GEOPOLITICAL & TRADE RISK: |
| • Universal, immediate drug access • Retaliatory trade measures |
| • Preservation of national health funds • Potential withdrawal of new drugs |
| • Scalable generic manufacturing capacity • International political pushback |
| • Measurable drop in patient mortality • Pressure during FTA negotiations |
+-----------------------------------------------------------------------------------+
Despite pressure, Thailand maintained its legal stance. Supported by international bodies such as the World Health Organization and UNAIDS, alongside global civil society organizations like Médecins Sans Frontières (MSF), Thai public health technocrats demonstrated that the country’s actions complied with the WTO TRIPS framework. Subsequent Thai administrations continued to assert this public-health primacy within international forums.
Modern Frontiers: Domestic Biomanufacturing and TRIPS-Plus Pressures
Thailand’s pharmaceutical security strategy has evolved from defensive legal measures toward proactive industrial capacity-building and complex trade diplomacy.
1. The Transition to Complex Biologics
As the disease burden shifted toward non-communicable diseases (NCDs), autoimmune conditions, and complex malignancies, the therapeutic landscape shifted from small-molecule generics to large-molecule biologics and biosimilars.
Because biosimilars require advanced fermentation, cellular expression systems, and extensive clinical trials, the GPO partnered with international manufacturers and domestic research institutes to localize production.
A notable example was the establishment of Siam Bioscience, which demonstrated the strategic value of domestic biomanufacturing when it pivoted to produce viral-vector COVID-19 vaccines during the 2021 pandemic emergency.
2. Free Trade Agreements and “TRIPS-Plus” Provisions
Thailand faces ongoing diplomatic tension regarding intellectual property chapters in bilateral and multilateral free trade agreements (FTAs), such as discussions surrounding the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP) and bilateral pacts with the European Union.
Multinational pharmaceutical coalitions have advocated for “TRIPS-Plus” measures, including:
-
Patent Term Extensions: Prolonging patent lifespans beyond the 20-year baseline to compensate for administrative regulatory delays.
-
Data Exclusivity: Restricting drug regulatory authorities from relying on originator clinical trial data to approve generic competitors, which delays generic market entry even after patent expiration.
-
Patent Linkage: Preventing the drug regulatory authority (Thai FDA) from registering generic medicines if an active patent dispute exists, shifting intellectual property enforcement onto public regulatory agencies.
Technocrats from the NHSO, the International Health Policy Program (IHPP), and civil society networks have regularly published empirical impact analyses arguing that accepting TRIPS-Plus provisions would significantly raise public pharmaceutical expenditures, potentially destabilizing the financial balance of the 30-Baht Universal Coverage Scheme.
Conclusion
Thailand’s public pharmaceutical supply chain demonstrates how middle-income countries can manage healthcare costs under universal access mandates. By combining the manufacturing capacity of the GPO, systematic HTA evaluations through the NLEM, consolidated procurement via the NHSO, and a willingness to invoke WTO flexibilities, Thailand established that drug access is an essential component of the human right to health. However, as international trade frameworks push for stricter intellectual property regimes, preserving the policy space needed to supply affordable, lifesaving therapeutics remains a central challenge for Thai public health governance.
Official Footnotes & Quality Sources
-
World Trade Organization (2001). Declaration on the TRIPS Agreement and Public Health. Adopted on 14 November 2001, Ministerial Conference, Fourth Session, Doha. WTO Document WT/MIN(01)/DEC/2. https://www.wto.org
-
Ministry of Public Health & National Health Security Office (2007). The 10 Burning Questions Regarding the Government Use of Patents on Drugs in Thailand. Nonthaburi: Ministry of Public Health, Royal Thai Government.
-
Tantivess, S., & Walt, G. (2008). The role of policy networks in the formulation of the universal access to antiretroviral therapy policy in Thailand: an analysis of the policy process. Health Policy and Planning, 23(5), 328–338. DOI: 10.1093/heapol/czn023
-
Yamabhai, I., Mohara, A., Tantivess, S., Chaisiri, K., & Teerawattananon, Y. (2011). Government use of patents in Thailand: The impacts on access to medicines and health expenditures. Health Policy, 102(2-3), 255–261. DOI: 10.1016/j.healthpol.2011.08.006
-
National Drug System Development Committee (2020). National Drug Policy B.E. 2563–2565 and the National List of Essential Medicines (NLEM) Selection Guidelines. Bangkok: Food and Drug Administration, Ministry of Public Health.